ThromboGenics preps marketing apps, possible drug launch; Allenex spins out companies

@FierceBiotech: Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility. Item | Follow @FierceBiotech

@JohnCFierce: Top execs at Novo Nordisk are getting a brand spanking new HQ building in Bagsvaerd. Story | Follow @JohnCFierce

@RyanMFierce: OpenClinica (open source EDC provider) strikes pact to bring software to evolving clinical trials market in China. Release | Follow @RyanMFierce

@MaureenFierce: IOM: Vaccines cause very few side effects. Report | Follow @MaureenFierce

>  Belgium's ThromboGenics says it is laying the foundation for a 2012 marketing launch for a new eye drug, ocriplasmin, as it readies marketing applications in Europe and the U.S. Story

> HemoShear has won a $4.3 million Phase II Small Business Innovation Research grant award from the National Heart, Lung and Blood Institute. "The grant will fund work profiling the effects of 50 known drugs upon the human blood vessel system (the vasculature) using HemoShear's proprietary human vascular surrogate system," according to a release. HemoShear release

> Citing tough financing conditions, Sweden's Allenex is transferring its holdings in NovaHep AB and Recopharma AB to Alden Impact Capital AG, Zurich, which is taking responsibility for their continued support. Release

Pharma News

@FiercePharma: Allergan got its bladder-control indication for Botox: FDA OKs wrinkle-fighter for incontinence in certain patients. News | Follow @FiercePharma

> GSK reps take OT suit to U.S. Supreme Court. Report

> Novo Nordisk blueprints $192M HQ in Bagsvaerd. Article

> Payers expect Provenge sales to stay flat. News

> Bladder nod for Botox first step to $400M in extra sales. Report

And Finally... Researchers say a new study indicates that an advanced brain scanning technology may be able to detect biomarkers for Alzheimer's long before the disease advances to a late stage. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.